Research Interest

Overview

We are seeking innovative immunopengineering approaches to address the critical issues in clinical cancer immunotherapy. Particular interest is to leverage biomaterial and nanotechnology , ultimately aiming at realizing their full potential for the clinical developments of the nano-immunotherapy. 

Nanomedicine modality 

Nanomedicine-enabled cancer therapy can directly kill cancer cells and promote the release of cancer antigens and danger signals, which stimulates innate and adaptive immune response  for cancer immunotherapy. The development of novel nanomedicine and delineating its anticancer mechanism can open a door for new rational-based immunoengineering strategies.

Nanoparticle platform 

Therapeutic cancer vaccine is a clinically relevant cancer immunotherapy that can generate endogenous cancer-specific immune response. It activates and augments anticancer T cell immunity by providing antigenic and co-stimulatory signals to professional antigen-presenting cells. Nanoparticle-based platforms can potentiate in vivo performance of cancer vaccine by improving target cell delivery of vaccine components in a spatio-temporally controlled manner.